Kissei Pharmaceutical マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Mutsuo Kanzawa

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	42.4yrs
CEOの所有権	3.6%
経営陣の平均在職期間	4.4yrs
取締役会の平均在任期間	9.4yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Mutsuo Kanzawa (75 yo)

42.4yrs

在職期間

Mr. Mutsuo Kanzawa is Chief Executive Officer of Kissei Pharmaceutical Co. Ltd and served as its President since June 1992. Mr. Kanzawa has been the Chairman of Kissei Pharmaceutical Co. Ltd. since June 20...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mutsuo Kanzawa	Chairman & CEO	no data	データなし	3.6% $ 37.6m
Yasuo Takehana	President	2.4yrs	データなし	0.038% $ 398.6k
Takahide Kitahara	GM of Financial Management Department	12.4yrs	データなし	0.021% $ 220.0k
Yoshio Furihata	Senior Advisor & Director	14.4yrs	データなし	0.030% $ 311.7k
Keiji Fukushima	Executive VP & Director	12.4yrs	データなし	0.028% $ 287.4k
Tetsu Takayama	Executive MD & Director	4.4yrs	データなし	0.037% $ 380.9k
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	2.4yrs	データなし	0.0040% $ 41.4k
Keiji Miyazawa	GM of Research Division & Director	2.4yrs	データなし	0.0042% $ 43.9k

4.4yrs

平均在職期間

62.5yo

平均年齢

経験豊富な経営陣: KSPH.Fの経営陣は経験豊富であると考えられます ( 4.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mutsuo Kanzawa	Chairman & CEO	42.4yrs	データなし	3.6% $ 37.6m
Yasuo Takehana	President	12.8yrs	データなし	0.038% $ 398.6k
Takahide Kitahara	GM of Financial Management Department	6.4yrs	データなし	0.021% $ 220.0k
Yoshio Furihata	Senior Advisor & Director	16.4yrs	データなし	0.030% $ 311.7k
Keiji Fukushima	Executive VP & Director	12.4yrs	データなし	0.028% $ 287.4k
Tetsu Takayama	Executive MD & Director	10.4yrs	データなし	0.037% $ 380.9k
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	2.4yrs	データなし	0.0040% $ 41.4k
Keiji Miyazawa	GM of Research Division & Director	2.4yrs	データなし	0.0042% $ 43.9k
Shigetaka Shimizu	Independent Outside Director	10.4yrs	データなし	0.0089% $ 92.6k
Sayuri Uchikawa	Independent Outside Director	4.4yrs	データなし	0.0040% $ 41.4k
Minoru Nomura	Independent Outside Director	8.4yrs	データなし	0.012% $ 124.2k
Yoshinori Otsuki	Independent Outside Director	2.4yrs	データなし	0.0028% $ 29.2k

9.4yrs

平均在職期間

63.5yo

平均年齢

経験豊富なボード: KSPH.Fの取締役会は経験豊富であると考えられます ( 9.4年の平均在任期間)。

Kissei Pharmaceutical マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Recent updates

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,400,000 shares, representing 3.17% for ¥5,292 million.

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 05, 2024

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 07, 2024

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024

Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Kissei Pharmaceutical Co., Ltd. Receives Marketing Authorization Approval in Japan for TAVALISSE Tab. 100Mg and 150Mg, an Oral Spleen Tyrosine Kinase Inhibitor

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter and Dividend Guidance for Year Ending of March 31, 2023, Payable Date on December 2, 2022

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2022

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Kissei Pharmaceutical Co., Ltd. Provides Earning Guidance for the First Half Ending September 30, 2022 and Full Year Ending March 31, 2023

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022

Kissei Pharmaceutical Co., Ltd. Releases Positive Topline Results from Its Phase 3 Clinical Trial in Japan

Kissei Pharmaceutical Co., Ltd. announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 15, 2020

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24